A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 490 participants.

Also called NCT02370537

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 490 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02370537
  • EudraCT 2014-003511-11
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Denmark, Hungary, Latvia, Poland, Slovakia, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02370537. Randomized; no masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2015-11 (actual). Results posted on 2017-01-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI
Acronym
PRECISE
Condition
Diabetes Mellitus, Type 2
Condition
Exocrine Pancreatic Insufficiency
Intervention (Drug)
Epanova® (omega-3 carboxylic acids)
Intervention (Drug)
Omacor® (omega-3-acid ethyl esters)
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02370537
Content hash
165b54efa6384e20e96bd0ba42e091219a573674927a444c5e47f9b003198a41